SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/45

Date: 13th August 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Intimation for approval to acquire 76 % shares of the target pharmaceutical company based out of Vizag - Vishakhapatanam; (the name shall be declared after the completion of the said due diligence and the definitive agreements are shared as per the requirement of privacy adopted by the seller)

Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('**SEBI Listing Regulations**'), this is to inform you that the Company has entered into an Memorandum of Understanding to acquire 1,24,64,000 equity shares of Rs.10/- each of the target company equivalent to 76% of the paid-up equity share capital of the said target company. The acquisition includes the acquisition of business, manufacturing plant, and the team; the same is subject to due diligence and other regulatory approvals. Upon completion of the acquisition, target company would become a subsidiary of the Sudarshan Pharma Industries Limited.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given in Annexure-A.

You are requested to take the same on record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**

Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director

SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Annexure-A.

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

SL NO	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	To acquire 1,24,64,000 equity shares of Rs.10/- each of the target company, equivalent to 76% of the paid-up target company - a manufacturing capacity plant, the business in the target company along with the team, which is subject to due diligence and other regulatory approvals.
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	The Plant has various necessary accreditations of US FDA, WHO Geneva, Anvisa, DCA (Government of Andhra Pradesh), and relevant ISO requirements.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Object of the acquisition is to achieve a backward integration and launch a complete end-to-end manufacturing capability in Sudarshan Pharma Industries Limited
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	10th October 2026
7	Nature of Consideration whether Cash consideration or share swap and details of the same	To be subscribed in cash and 40 lakh shares of Sudarshan Pharma Industries Limited offered by the promoters of Sudarshan Pharma Industries Limited.
8	Cost of acquisition or the price at which the shares are acquired.	Cost of acquisition shall be based upon valuation and other due diligence.

Sudarshan Pharma Industries Limited

9	Percentage of shareholding control acquired and /or number of shares acquired	NA
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: The Company is in process to acquire a manufacturing plant. Turnover FY — Rs. in Lakhs 2025-26 — 15,437 2024-25 — 15,355 2023-24 — 19,247 Containing 4 manufacturing blocks with the total Manufacturing capacity of 576.10 KL

For, **Sudarshan Pharma Industries Limited**

Hemal Mehta
Chairman & Managing Director

Sudarshan Pharma Industries Limited